Levodopa/Carbidopa/Entacapon Rivopharm

Levodopa, the active ingredient in Levodopa/Carbidopa/Entacapone Rivopharm, is an antiparkinson agent presented as a combination tablet for oral use. It treats Parkinson's disease by restoring dopamine levels in patients with this neurodegenerative disorder.

GNH USA supplies Levodopa/Carbidopa/Entacapone Rivopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa/Entacapone is indicated for Parkinson's disease and related motor complications. - Parkinson's disease: improves overall motor control and reduces bradykinesia. - Parkinson's disease with motor fluctuations: decreases "off" time and prolongs symptom relief. - Early-stage Parkinson's disease: delays the need for higher levodopa doses by enhancing central availability.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Headache - Orthostatic hypotension - Insomnia

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or psychosis - Severe hypotension or syncope - Neuroleptic malignant syndrome - Significant liver enzyme elevation - Allergic reactions such as rash, angioedema, or anaphylaxis

Use of Levodopa/Carbidopa/Entacapone requires careful monitoring. - Blood pressure monitoring: watch for orthostatic hypotension, especially at treatment initiation. - Liver function assessment: evaluate enzymes periodically due to potential hepatic effects. - Psychiatric evaluation: monitor for hallucinations, confusion, or mood changes. - Renal impairment dose adjustment: consider reduced dosing in severe renal dysfunction. - Discontinuation caution: avoid abrupt cessation to prevent withdrawal symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Levodopa/Carbidopa/Entacapone interacts with several drug classes.

Major Interactions (Avoid): - MAO‑B inhibitors (e.g., selegiline, rasagiline): risk of hypertensive crisis. - Non‑selective MAO inhibitors (e.g., phenelzine): can cause severe hypertension. - Antipsychotics (e.g., haloperidol, risperidone): may diminish levodopa efficacy and worsen motor symptoms.

Moderate Interactions (Monitor Closely): - Iron or calcium supplements: reduce levodopa absorption; separate dosing by at least 2 hours. - Antihypertensive agents: additive hypotensive effect may require dose adjustment. - Diuretics: can influence fluid balance and blood pressure. - SSRIs or SNRIs: monitor for serotonin syndrome when combined with MAO‑B inhibitors.